Background: Neuroactive steroids (NAS) affect neurotransmitter systems and cognition; thus, they play role in etiopathogenesis of psychiatric disorders. Aims: The primary aim was to examine cognition and effects of NAS on cognitive functioning in first-episode psychosis patients and in their healthy siblings. The secondary aims were to verify whether cognitive deficit is an endophenotype of psychosis and whether higher NAS levels represent a high-risk factor for psychosis. Methods: Studied participants were 1) patients with first episode of psychosis, 2) healthy siblings of the patients, and 3) matching healthy controls. Study procedures included administration of a battery of neuropsychological tests assessing six cognitive domains and examination of NAS plasma levels [cortisol (CORT), 11-deoxycorticosterone (DOC), testosterone (TEST), dehydroepiandrostendione (DHEA), dihydrotestosterone (DHT), and progesterone (PROG)]. Results: A total of 67 subjects were analyzed (16 patients, 22 siblings, and 29 controls). Significant group differences were found in most of the cognitive domains; the patients had the lowest scores. The Kruskal-Wallis test revealed significant group differences in CORT levels (p < 0.01), TEST (p < 0.01), and DHT (p < 0.001); no difference was found in PROG, DHEA, and DOC. All cognitive domains, except for attention, were affected by the NAS levels. CORT levels of patients correlated with speed of processing (r = 0.55) and working memory (r = 0.52), while PROG levels correlated with abstraction (r = -0.63). In siblings, there was a negative correlation between TEST levels and verbal memory (r = -0.51) and PROG with attention (r = -0.47). Conclusions: Our results verified that individual domains of cognitive deficit (abstraction and verbal memory) can be considered as an endophenotype of psychosis. Higher levels of cortisol and testosterone in siblings are consistent with high-risk states for psychosis. Multiple interactions between NAS and cognitive functioning, particularly memory functions, were observed. Study limitations (small sample size and administration of antipsychotic medication) did not allow us to establish unequivocally NAS as an endophenotype.

1st Faculty of Medicine Charles University Prague Czechia

3rd Faculty of Medicine Charles University Prague Czechia

Faculty of Arts Charles University Prague Czechia

Faculty of Arts Masaryk University Brno Czechia

Faculty of Social Studies Masaryk University Brno Czechia

National Institute of Mental Health Klecany Czechia

University of Chemistry and Technology Prague Czechia

Zobrazit více v PubMed

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull (2009) 35(3):549–62. 10.1093/schbul/sbp006 PubMed DOI PMC

Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol (2006) 26(4–6):365–84. 10.1007/s10571-006-9062-8 PubMed DOI PMC

Taylor SF, Tso IF. GABA abnormalities in schizophrenia: a methodological review of in vivo studies. Schizophr Res (2015) 167(1–3):84–90. 10.1016/j.schres.2014.10.011 PubMed DOI PMC

Eggers AE. A serotonin hypothesis of schizophrenia. Med Hypotheses (2013) 80(6):791–4. 10.1016/j.mehy.2013.03.013 PubMed DOI

Baulieu EE. Steroid hormones in the brain: several mechanisms. In: Fuxe K, Gustafson JA, Wetterberg L, editors. Steroid hormone regulation of the brain. New York: Pergamon Press; (1981). p. 3–14. 10.1016/B9780-08-026864-4.50007-4 DOI

Banga PV, Patil CY, Deshmukh GA, Chandaliya KC, Baig MS, Doifode SM. Biosynthesis, mechanism of action and clinical importance of neuroactive steroids: pearls from literature. Int J Nutr Pharmacol Neurol Dis (2013) 3(2):77–86. 10.4103/2231-0738.112826 DOI

Tuem KB, Atey TM. Neuroactive steroids: receptor interactions and responses. Front Neurol (2017) 8:442. 10.3389/fneur.2017.00442 PubMed DOI PMC

Dubrovsky BO. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry (2005) 29(2):169–92. 10.1016/j.pnpbp.2004.11.001 PubMed DOI

Uzunova V, Sampson L, Uzunov DP. Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology (2006) 186:351–61. 10.1007/s00213-005-0201-6 PubMed DOI

Longone P, di Michele F, D’Agati E, Romeo E, Pasini A, Rupprecht R. Neurosteroids as neuromodulators in the treatment of anxiety disorders. Front Endocrinol (2011) 2:55. 10.3389/fendo.2011.00055 PubMed DOI PMC

Ugale RR, Hirani K, Morelli M, Chopde CT. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology (2004) 29:1597–609. 10.1038/sj.npp.1300460 PubMed DOI

Cai HL, Cao T, Zhou X, Yao JK. Neurosteroids in schizophrenia: pathogenic and therapeutic implications. Front Psychiatry (2018) 9:73. 10.3389/fpsyt.2018.00073 PubMed DOI PMC

Ritsner MS. The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience (2011) 191:91–100. 10.1016/j.neuroscience.2011.04.017 PubMed DOI

Cai H, Zhou X, Dougherty GG, Reddy RD, Haas GL, Montrose DM, et al. Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naïve patients with schizophrenia. Psychoneuroendocrinology (2018) 90:43–51. 10.1016/j.psyneuen.2018.02.004 PubMed DOI PMC

Misiak B, Frydecka D, Loska O, Moustafa AA, Samochowiec J, Kasznia J, et al. Testosterone, DHEA and DHEA-S in patients with schizophrenia: a systematic review and meta-analysis. Psychoneuroendocrinology (2018) 89:92–102. 10.1016/j.psyneuen.2018.01.007 PubMed DOI

Ritsner MS. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci Ther (2010) 16(1):32–44. 10.1111/j.1755-5949.2009.00118.x PubMed DOI PMC

Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology (2003) 28(1):1–13. 10.1038/sj.npp.1300015 PubMed DOI

Nechmad A, Maayan R, Ramadan E, Morad O, Poyurovsky M, Weizman A. Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels. Eur Neuropsychopharmacol (2003) 13:29–31. 10.1016/S0924-977X(02)00077-9 PubMed DOI

Hill M, Lukáč D, Lapčík O, Sulcová J, Hampl R, Pouzar V, et al. Age relationships and sex differences in serum levels of pregnenolone and 17-hydroxypregnenolone in normal subjects. Clin Chem Lab Med (2005) 37(4):439–47. 10.1515/CCLM.1999.072 PubMed DOI

Cechnicki A, Hanuszkiewicz I, Polczyk R, Bielańska A. Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia. Med Sci Monit (2011) 17(5):CR277–283. 10.12659/MSM.881768 PubMed DOI PMC

Addington J, Van Mastrigt S, Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol Med (2004) 34(2):277–84. 10.1017/S0033291703001156 PubMed DOI

McGorry PD. Early intervention in psychosis: obvious, effective, overdue. J Nerv Ment Dis (2015) 203(5):310–8. 10.1097/NMD.0000000000000284 PubMed DOI PMC

Waddington JL, Corvin AP, Donohoe G, O’Tuathaigh CMP, Mitchell KJ, Gill M. Functional genomics and schizophrenia: endophenotypes and mutant models. Psychiatr Clin North Am (2007) 30(3):365–99. 10.1016/j.psc.2007.04.011 PubMed DOI

Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry (2003) 160(4):636–45. 10.1176/appi.ajp.160.4.636 PubMed DOI

Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: a selective review. Schizophr Res (2009) 109(1–3):24–37. 10.1016/j.schres.2009.01.016 PubMed DOI PMC

Hou CL, Xiang YT, Wang ZL, Everall I, Tang Y, Yang C, et al. Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. Schizophr Res (2016) 174(1–3):71–6. 10.1016/j.schres.2016.04.034 PubMed DOI

Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med (2017) 47(6):1030–40. 10.1017/S0033291716003366 PubMed DOI

Ritsner MS, Strous RD. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled crossover trial with DHEA. J Psychiatr Res (2010) 44(2):75–80. 10.1016/j.jpsychires.2009.07.002 PubMed DOI

Kreinin A, Bawakny N, Ritsner MS. Adjunctive pregnenolone ameliorates the cognitive deficits in recent-onset schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Clin Schizophr Relat Psychoses (2017) 10(4):201–10. 10.3371/CSRP.KRBA.013114 PubMed DOI

Strous RD, Stryjer R, Maayan R, Gal G, Viglin D, Katz E, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology (2007) 32(2):96–105. 10.1016/j.psyneuen.2006.11.002 PubMed DOI

World Health Organization The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; (1992).

Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 165(2):203–13. 10.1176/appi.ajp.2007.07010042 PubMed DOI

Rodriguez M, Fajnerová I, Sedláková K, Dorazilová A, Voráčková V, Paštrňák M, et al. Cluster analysis and correlations between cognitive domains: cognitive performance in a Czech sample of first episodes schizophrenia spectrum disorders—preliminary results. Psychiatrie (2017) 21(1):4–11.

Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry (2000) 48:1121–32. 10.1016/S0006-3223(00)01052-0 PubMed DOI

Havelka D, Prikrylova-Kucerova H, Prikryl R, Ceskova E. Cognitive impairment and cortisol levels in first-episode schizophrenia patients. Stress (2016) 19(4):383–9. 10.1080/10253890.2016.1193146 PubMed DOI

Allott KA, Yuen HP, Bartholomeusz CF, Rapado-Castro M, Phassouliotis C, Butselaar F, et al. Stress hormones and verbal memory in young people over the first 12 weeks of treatment for psychosis. Psychiatry Res (2018) 260:60–6. 10.1016/j.psychres.2017.11.044 PubMed DOI

Moore L, Kyaw M, Vercammen A, Lenroot R, Kulkarni J, Curtis J, et al. Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology (2013) 38(9):1717–28. 10.1016/j.psyneuen.2013.02.007 PubMed DOI

Bratek A, Koźmin-Burzyńska A, Krysta K, Cierpka-Wiszniewska K, Krupka-Matuszczyk I. Effects of hormones on cognition in schizophrenic male patients—preliminary results. Psychiatr Danub (2015) 27(1):261–5. PubMed

Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res (2013) 150(1):42–50. 10.1016/j.schres.2013.07.009 PubMed DOI PMC

Aas M, Dazzan P, Mondelli V, Melle I, Murray RM, Pariante CM. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front Psychiatry (2014) 4:182. 10.3389/fpsyt.2013.00182 PubMed DOI PMC

Rodriguez M, Zaytseva Y, Cvrčková A, Dvořaček B, Dorazilová A, Jonáš J, et al. Cognitive profiles and functional connectivity in first-episode schizophrenia spectrum disorders: linking behavioural and neuronal data. Front Psychol (2019) 10:689. 10.3389/fpsyg.2019.00689 PubMed DOI PMC

Snitz BE, Macdonald AW, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull (2006) 32(1):179–94. 10.1093/schbul/sbi048 PubMed DOI PMC

Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, et al. Neuropsychology of the prodrome to psychosis in the NAPLS Consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry (2010) 67(6):578–88. 10.1001/archgenpsychiatry.2010.66 PubMed DOI PMC

Chu AOK, Chang WC, Chan SKW, Lee EHM, Hui CLM, Chen EYH. Comparison of cognitive functions between first-episode schizophrenia patients, their unaffected siblings and individuals at clinical high-risk for psychosis. Psychol Med (2018) 18:1–8. 10.1017/S0033291718002726 PubMed DOI

Cannon TD, Bearden CE, Hollister JM, Rosso IM, Sanchez LE, Hadley T. Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull (2000) 26(2):379–93. 10.1093/oxfordjournals.schbul.a033460 PubMed DOI

Kulkarni S, Jain S, Janardhan Reddy YC, Kumar KJ, Kandavel T. Impairment of verbal learning and memory and executive function in unaffected siblings of probands with bipolar disorder. Bipolar Disord (2010) 12(6):647–56. 10.1111/j.1399-5618.2010.00857.x PubMed DOI

Barbaccia ML, Affricano D, Purdy RH, Maciocco E, Spiga F, Biggio G. Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology (2001) 25(4):489–97. 10.1016/S0893-133X(01)00254-8 PubMed DOI

Roke Y, van Harten PN, Buitelaar JK, Tenback DE, de Rijke YB, Boot AM. Antipsychotic-induced hyperprolactinemia and testosterone levels in boys. Horm Res Paediatr (2012) 77(4):235–40. 10.1159/000337910 PubMed DOI

van Rijn S, Aleman A, de Sonneville L, Sprong M, Ziermans T, Schothorst P, et al. Neuroendocrine markers of high risk for psychosis: salivary testosterone in adolescent boys with prodromal symptoms. Psychol Med (2011) 41(9):1815–22. 10.1017/S0033291710002576 PubMed DOI

Sinclair D, Purves-Tyson TD, Allen KM, Weickert CS. Impacts of stress and sex hormones on dopamine neurotransmission in the adolescent brain. Psychopharmacology (Berl) (2014) 231(8):1581–99 10.1007/s00213-013-3415-z PubMed DOI PMC

Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry (2009) 66(1):13–20. 10.1001/archgenpsychiatry.2008.514 PubMed DOI

Carol EE, Mittal VA. Resting cortisol level, self-concept, and putative familial environment in adolescents at ultra high-risk for psychotic disorders. Psychoneuroendocrinology (2015) 57:26–36. 10.1016/j.psyneuen.2015.03.018 PubMed DOI PMC

Yıldırım O, Dogan O, Semiz M, Kilicli F. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives. Psychiatry Clin Neurosci (2011) 65:584–91. 10.1111/j.1440-1819.2011.02252.x PubMed DOI

Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead KS, Cornblatt BA, et al. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry (2013) 74(6):410–7. 10.1016/j.biopsych.2013.02.016 PubMed DOI PMC

Colciago A, Casati L, Negri-Cesi P, Celotti F. Learning and memory: steroids and epigenetics. J Steroid Biochem Mol Biol (2015) 150:64–85. 10.1016/j.jsbmb.2015.02.008 PubMed DOI

Samaras N, Samaras D, Frangos E, Forster A, Philippe J. A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial? Rejuvenation Res (2013) 16(4):285–94. 10.1089/rej.2013.1425 PubMed DOI PMC

Halari R, Kumari V, Mehrotra R, Wheeler M, Hines M, Sharma T. The relationship of sex hormones and cortisol with cognitive functioning in Schizophrenia. J Psychopharmacol (2004) 18(3):366–74. 10.1177/026988110401800307 PubMed DOI

MacLusky NJ, Hajszan T, Prange-Kiel J, Leranth C. Androgen modulation of hippocampal synaptic plasticity. Neuroscience (2006) 138(3):957–65. 10.1016/j.neuroscience.2005.12.054 PubMed DOI

Chen CY, Wu CC, Huang YC, Hung CF, Wang LJ. Gender differences in the relationships among neurosteroid serum levels, cognitive function, and quality of life. Neuropsychiatr Dis Treat (2018) 14:2389–99. 10.2147/NDT.S176047 PubMed DOI PMC

Bicikova M, Hill M, Ripova D, Mohr P, Hampl R. Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol (2013) 133:77–83. 10.1016/j.jsbmb.2012.08.009 PubMed DOI